Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
August 20, 2022 at 15:01 PM EDT
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront).
